Nevro Corp. (NVRO)
After hours:
| Previous close | 9.39 |
| Open | 9.44 |
| Bid | 7.80 x 800 |
| Ask | 10.21 x 900 |
| Day's range | 9.33 - 9.52 |
| 52-week range | 8.93 - 28.42 |
| Volume | |
| Avg. volume | 522,771 |
| Market cap | 344.882M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on May 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro's common stock to twenty-six new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Pla
- PR Newswire
Nevro to Present at BofA Securities 2024 Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024. The company's formal presentation will begin at 9:20 am PDT (12:20 am EDT).
- PR Newswire
Nevro Reports First-Quarter 2024 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The company also announced additional restructuring steps to advance its strategy and accelerate profitability, raised its adjusted EBITDA guidance and reaffirmed its revenue guidance for the full-year 2024, and announced that Christofer Christoforou has been promoted to the newly created Ch
